SOCS1 depletion drives osteosarcoma stemness and chemoresistance by suppressing ACTN4 degradation.

It is found that wortmannin, an inhibitor of ACTN4, could markedly block the effect of SOCS1 silencing on osteosarcoma aggressiveness, and offers promising therapeutic targets for potentiating chemosensitivity in osteosarcoma.